Table 1.
Primary and secondary endpoints
| Variables | Omecamtiv mercabil | Placebo | Hazard ratio or difference | P values |
|---|---|---|---|---|
| (n = 4120) | (n = 4112) | (95% CI) | ||
| Primary or composite outcome—n (%) | 1523 (37) | 1607 (39.1) | 0.92 (0.86–0.99) | 0.025 |
| Cardiovascular death as first event | 346 (8.4) | 371 (9.0) | ||
| Hospitalization for heart failure as first event | 1107 (26.9) | 1133 (27.6) | ||
| Urgent visit for heart failure as first event | 70 (1.7) | 103 (2.5) | ||
| Secondary outcome | ||||
| Cardiovascular death—n (%) | 808 (19.6) | 798 (19.4) | 1.01 (0.92–1.11) | 0.86 |
| Variation of KCCQ at 24 weeks | 0.03 | |||
| Inpatient | 23.7 ± 0.7 | 21.2 ± 0.7 | 2.5 (0.5–4.5) | |
| Outpatient | 5.8 ± 0.3 | 6.3 ± 0.3 | –0.5 (–1.4 to 0.5) | |
| First hospitalization for heart failure | 1142 (27.7) | 1179 (28.7) | 0.95 (0.87–1.03) | NA |
| All-causes-mortality—n (%) | 1067 (25.9) | 1065 (25.9) | 1.00 (0.92–1.09) | NA |